Correspondence 0001104659-24-103101 from BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883) (BCLI)
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883)
Date: Sept. 26, 2024 · CIK: 0001137883 · Accession: 0001104659-24-103101
AI Filing Summary & Sentiment
File numbers found in text: 333-282172
Letter
Brainstorm Cell Therapeutics, Inc.
1325 Avenue of Americas, 28th Floor
New York, New York 10019
(201) 488-0460
September 26, 2024
VIA EDGAR SUBMISSION
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Brainstorm Cell Therapeutics, Inc. (the “Company”)
Registration Statement on Form S-3 (File No. 333-282172) (the “Registration Statement”)
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, the Company hereby requests that the U.S. Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement to become effective on Friday, September 27, 2024, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable, unless the Company notifies you otherwise prior to such time.
If you have any questions regarding this request, please contact our outside counsel, Faith L. Charles of Thompson Hine LLP, by telephone at (212) 908-3905 or via email at Faith.Charles@ThompsonHine.com. Please also call Faith L. Charles as soon as the Company’s Registration Statement has been declared effective. Thank you for your attention to this matter.
Sincerely,
BRAINSTORM CELL THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Brainstorm Cell Therapeutics, Inc.
1325 Avenue of Americas, 28th Floor
New York, New York 10019
(201) 488-0460
September 26, 2024
VIA EDGAR SUBMISSION
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Brainstorm Cell Therapeutics, Inc. (the “Company”)
Registration Statement on Form S-3 (File No. 333-282172) (the “Registration Statement”)
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended,
the Company hereby requests that the U.S. Securities and Exchange Commission take appropriate action to cause the above-referenced Registration
Statement to become effective on Friday, September 27, 2024, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable, unless
the Company notifies you otherwise prior to such time.
If you have any questions regarding this request, please contact our
outside counsel, Faith L. Charles of Thompson Hine LLP, by telephone at (212) 908-3905 or via email at Faith.Charles@ThompsonHine.com.
Please also call Faith L. Charles as soon as the Company’s Registration Statement has been declared effective. Thank you for your
attention to this matter.
Sincerely,
BRAINSTORM CELL THERAPEUTICS, INC.
By:
/s/ Chaim Lebovits
Name:
Chaim Lebovits
Title:
Chief Executive Officer
cc: Faith L. Charles, Thompson Hine LLP